Here’s Insiders Fund’s Thesis on Insulet Corporation (PODD)
Alpha Wealth Funds, LLC's "Insiders Fund" discussed Insulet Corporation (NASDAQ:PODD) in its Q1 2026 investor letter. While the fund acknowledged PODD's leadership in medical technology with its Omnipod Insulin Management System, it indicated a preference for AI stocks with higher return potential. Insider transactions for PODD were noted, and the company's Q1 2026 revenue increased by 34% to $762 million.
Insulet Corporation (PODD) Announces Amendments to Bylaws and Annual Meeting Results
Insulet Corporation (PODD) has announced significant updates following its 2026 Annual Meeting of Stockholders, including immediate amendments to its Bylaws. These amendments designate the Court of Chancery of Delaware as the exclusive forum for certain legal actions and federal district courts for U.S. Securities Act claims. Shareholders also elected three Class I directors, approved executive compensation, and ratified PricewaterhouseCoopers LLP as the independent accounting firm for 2026.
Insulet (PODD) director awarded 1,660 RSUs in deferred stock grant
Insulet (PODD) director Robert Luther Huffines was granted 1,660 Restricted Stock Units (RSUs) as an annual equity award at no cash cost. These RSUs will vest in full on April 30, 2027, and will convert into common shares after his board service ends, as per his deferral election. Following this transaction, Huffines beneficially owns 2,298 common shares directly.
Insulet (NASDAQ: PODD) amends bylaws and confirms 2026 shareholder voting outcomes
Insulet Corporation (NASDAQ: PODD) has amended its bylaws to designate Delaware courts as the exclusive forum for specific corporate disputes and federal courts for claims under the U.S. Securities Act of 1933. At its 2026 annual meeting, shareholders elected three Class I directors, approved executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026. A strong quorum of 89.19% was present, with 61,782,973 shares represented.
Insulet (PODD) director granted 1,660 RSUs, total holdings now 3,818 shares
Insulet director Frederick Wayne A.I. was granted 1,660 Restricted Stock Units (RSUs) as an annual equity award, with no cash paid per share. These RSUs will vest in full on April 30, 2027, and the settlement is deferred until his board service ends. Following this grant, Frederick Wayne A.I. directly holds a total of 3,818 shares of Insulet common stock.
Insulet (PODD) price target decreased by 21.96% to 270.07
This article reports a significant decrease in the price target for Insulet (PODD) by 21.96%, bringing it down to $270.07. The specific reasons or analyst behind this adjustment are not provided in this brief update.
Insulet Corp stock (US45784P1012): William Blair starts coverage as after-hours drop tests investor
Insulet Corp (US45784P1012) experienced an after-hours stock drop following a recent rally, despite William Blair initiating coverage with an Outperform rating. The company, known for its Omnipod tubeless insulin pump systems, showcased strong operational metrics with revenue growth in the low-30% range and high gross margins. This article highlights Insulet's business model, competitive landscape, and its relevance for US investors navigating the balance between growth prospects, competitive pressures, and valuation volatility in the medtech sector.
Insulet Corp. stock outperforms competitors on strong trading day
Insulet Corp. (PODD) saw its stock increase by 1.28% to $156.59 on Wednesday, outperforming the broader market. This gain contributed to the stock's third consecutive day of increases, with the S&P 500 and Dow Jones also experiencing positive trading sessions.
William Blair initiates Insulet stock coverage with Outperform rating
William Blair has initiated coverage of Insulet Corporation (NASDAQ:PODD) with an Outperform rating, noting the stock trades at a discount compared to peers despite faster sales growth. The firm acknowledges investor concerns regarding potential market share loss and the impact of GLP-1 medications on the type 2 diabetes market but sees upside in Insulet's initiatives and pipeline. Despite a recent stock decline, Insulet reported strong financial results, though several analysts have adjusted price targets reflecting mixed outlooks.
William Blair initiates Insulet stock coverage with Outperform rating By Investing.com
William Blair has initiated coverage on Insulet Corporation (NASDAQ:PODD) with an Outperform rating, noting the stock is undervalued compared to peers despite faster sales growth. The firm acknowledges investor concerns regarding potential market share loss and the impact of GLP-1 medications on the type 2 diabetes market, but sees upside from salesforce expansion, pipeline advances, and international growth. Insulet recently reported strong Q1 sales, surpassing analyst estimates, though some firms have adjusted price targets due to growth deceleration concerns.
William Blair Assumes Insulet Corporation (PODD) at Outperform
William Blair analyst Steve Lichtman initiated coverage on Insulet Corporation (PODD) with an Outperform rating. The article, however, is premium content, so specific details of the analyst's comments are not immediately available without a subscription.
Insulet Corp. stock underperforms Tuesday when compared to competitors despite daily gains
Insulet Corp. (PODD) stock gained 1.39% on Tuesday, closing at $154.61, despite an overall downturn in the stock market where the S&P 500 and Dow Jones Industrial Average both fell. Despite its daily gains, Insulet Corp. underperformed in comparison to its competitors. This marks the second consecutive day of gains for the stock.
What Insulet (PODD)'s Buybacks, Raised Guidance and Riyadh Hub Mean For Shareholders
Insulet Corporation recently reported strong Q1 results with $761.7 million in revenue and $91.1 million in net income, confirmed upgraded 2026 revenue growth guidance, completed a significant share repurchase, and established a regional headquarters in Riyadh. These moves aim to strengthen the company's financial position, signal confidence in its growth trajectory, and expand its reach into international diabetes markets, particularly focusing on recurring revenue from its Omnipod franchise. The success of the Riyadh hub will be crucial for its international expansion strategy.
Insulet Corp (PODD) Shares Surge 3.5% -- What GF Score of 82 Tel
Insulet Corp (PODD) shares surged 3.5% to $152.49, marking it as significantly undervalued with a GF Value™ of $387.06 and a 60.6% upside potential, despite recent price declines. The company holds a strong GF Score™ of 82/100, driven by excellent growth and profitability, while insider purchases of $1.5 million signify high confidence in its future. The stock's current P/E of 35.5x is also significantly lower than its historical median, reinforcing its undervalued status.
Insulet Corp. stock outperforms competitors on strong trading day
Insulet Corp. (PODD) saw its stock rise by 3.41% to $152.49 on Monday, outperforming the broader market during a mixed trading session. This gain broke a three-day losing streak for the company's shares. The Dow Jones Industrial Average closed up 0.32%, while the S&P 500 Index fell 0.07%.
New Philips heart imaging cuts X-ray dose by over half in complex procedures
Philips will present new imaging, physiology, and AI-enabled guidance solutions at EuroPCR 2026, aimed at reducing X-ray radiation doses by over 50% in complex coronary and structural heart procedures. Key innovations include SmartIQ technology, IntraSight Plus, and DeviceGuide, designed to improve workflow efficiency and patient care while minimizing radiation exposure for both patients and staff. The company emphasizes integrated solutions to manage procedural complexity without compromising image quality or clinical confidence.
Insulet Corporation Stock 12‑Month Price Target Cut to $245.17, Implies 66% Upside
Twenty-four analysts have lowered Insulet Corporation's average 12-month price target from $248.5 to $245.17, with predictions ranging from $175 to $360 per share. Based on the closing price on May 15, this new target suggests a potential upside of approximately 66%. Despite the target cut, the consensus rating from 28 analysts remains "Buy," with 24 buys, 3 holds, and 1 sell.
Insulet (PODD) Stock Gains on Benchmark Upgrade and Riyadh HQ Opening | 2026 - News and Statistics
Insulet Corporation's (NASDAQ:PODD) stock gained after Benchmark initiated coverage with a Buy rating and a $250 price target, signaling a significant upside. Concurrently, Insulet announced the opening of its regional headquarters in Riyadh, Saudi Arabia, to manage operations in the Middle East and North Africa, indicating a strategic market expansion. Despite the 3% gain, the stock remains 43.9% down year-to-date and 55% below its 52-week high from September 2025.
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
DexCom outlined its long-term growth plan during its 2026 Investor Day, targeting over 10% annual revenue growth through 2030, along with margin expansion and increased free cash flow. Key initiatives include the rollout of the G7 15 Day product, the anticipated launch of the G8 continuous glucose monitor around late 2027 or early 2028, and significant expansion of insurance coverage, particularly for Type 2 diabetes patients not using insulin. The company also announced a $1 billion share repurchase program for 2026 and committed to returning at least 50% of annual free cash flow to buybacks going forward.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)
Three analysts from Bank of America Securities have provided bullish outlooks on healthcare companies Henry Schein (HSIC), Insulet (PODD), and Gilead Sciences (GILD). Henry Schein received a Moderate Buy consensus with a 25.2% upside, Insulet a Moderate Buy with a 76.2% upside, and Gilead Sciences a Strong Buy with a 19.5% upside, highlighting positive sentiment in the sector.
Insulet Corporation Trade Ideas — BOATS:PODD
This article compiles several trading ideas and analyses for Insulet Corporation (PODD) from various contributors on TradingView. It covers fundamental and technical analysis, including earnings growth, sales figures, resistance and support levels, and chart patterns like cup and handle formations. The contributors offer diverse perspectives on potential entry points, profit targets, and stop-loss levels, indicating both bullish and cautious sentiments for the stock.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)
Three analysts from Bank of America Securities have issued bullish ratings on Henry Schein (HSIC), Insulet (PODD), and Gilead Sciences (GILD) within the Healthcare sector. Allen Lutz maintained a Buy rating on Henry Schein, Travis Steed maintained a Buy rating on Insulet, and Tazeen Ahmad maintained a Buy rating on Gilead Sciences, with all three stocks showing significant upside potential based on average price targets.
Insulet (PODD) price target decreased by 21.96% to 270.07
This article reports that Insulet Corporation's (PODD) price target has been reduced by 21.96%, bringing it down to $270.07. No further details about the reasons for this adjustment are provided in the snippet.
Insulet (PODD) CEO McEvoy uses 1,411 shares to cover RSU taxes
Insulet Corp's CEO, Ashley McEvoy, reported a routine tax-related share disposition where 1,411 shares of common stock were withheld on May 13, 2026, at $148.84 per share. This action covered tax obligations arising from vested restricted stock units, impacting neither positively nor negatively the overall sentiment. Following this, McEvoy directly owns 22,551 shares and indirectly holds 4 additional shares through a trust.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)
This article highlights bullish sentiments from financial analysts on three healthcare companies: Henry Schein (HSIC), Insulet (PODD), and Gilead Sciences (GILD). Analysts from Bank of America Securities maintained Buy ratings for all three, citing potential upsides ranging from 19.5% to 76.2% based on average price targets. The report details specific analyst ratings, price targets, and consensus recommendations for each company.
A Look At Insulet (PODD) Valuation After Strong Q1 Results And Raised Revenue Guidance
Insulet (PODD) reported strong Q1 results with US$761.7 million in revenue and US$91.1 million in net income, and raised its full-year 2026 revenue guidance. Despite this, the stock price has fallen significantly, leading to questions about whether the market is overlooking its potential or correctly pricing future growth. Valuation models show mixed signals, with some suggesting the stock is undervalued while others point to rich expectations based on its P/E ratio.
Why Goldman Sachs Trimmed Insulet Corporation (PODD) Price Target Despite Strong Q1 Results
Goldman Sachs has reduced its price target for Insulet Corporation (NASDAQ:PODD) to $237 from $277, while maintaining a Buy rating. This adjustment comes despite strong Q1 results and updated guidance, due to concerns about the growth trajectory after Q2 U.S. revenue guidance fell short of full-year expectations. The company also attributed a slower start to the year to stronger seasonality effects linked to insurance deductible resets.
Insulet stock (US45784P1012): 52-week low after strong quarterly growth raises questions for investo
Insulet's stock recently hit a new 52-week low despite the company reporting strong Q4 2025 revenue and earnings growth, driven by its Omnipod insulin delivery systems. This paradoxical situation has led to increased scrutiny from US investors regarding the stock's valuation, competitive landscape, and long-term growth durability. While institutional investors like Capital Research Global Investors maintain significant positions, the market appears cautious, weighing growth prospects against potential risks in the highly competitive diabetes technology sector.
(PODD) as a Liquidity Pulse for Institutional Tactics
This article provides an institutional analysis of Insulet Corporation (NASDAQ: PODD), highlighting weak sentiment across all horizons and supporting a short bias. It details three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and key findings regarding downside risk and support/resistance levels.
Insulet (PODD) price target decreased by 21.96% to 270.07
This article reports a significant 21.96% decrease in Insulet's (PODD) stock price target, bringing it down to $270.07. This adjustment suggests a revised outlook from analysts regarding the company's future performance or valuation.
Insulet Corp stock (US45784P1012): Hits 52-week low at $148.24
Insulet Corp (NASDAQ:PODD) shares recently hit a 52-week low of $148.24 despite strong Q4 2025 earnings which saw a 31.2% revenue growth to $783.8 million, exceeding estimates. Capital Research Global Investors also disclosed a 2.4% passive stake in the company. Insulet specializes in Omnipod insulin delivery systems and continues to show competitive strength in the expanding diabetes care market.
Some May Be Optimistic About Insulet's (NASDAQ:PODD) Earnings
Insulet Corporation's recent earnings report was disappointing due to soft headline numbers, but investors might be overlooking encouraging factors. The company incurred an US$87m expense from unusual items, which are often one-off and suggest that future profits could be higher if these expenses don't recur. Analysts predict improved profitability, and Insulet's EPS are showing strong growth.
Capital Research holds 2.4% of Insulet (NASDAQ: PODD) in Schedule 13G/A
Capital Research Global Investors has filed an amended Schedule 13G (13G/A) indicating a beneficial ownership of 1,669,556 shares in Insulet Corp. (NASDAQ: PODD), which represents 2.4% of the company's outstanding common stock. This filing is a routine passive institutional disclosure, showing sole voting power over 1,664,274 shares and sole dispositive power over all 1,669,556 shares. The reported stake is below the 5% threshold typically associated with more active ownership filings.
Insulet Corporation stock hits 52-week low at 148.24 USD By Investing.com
Insulet Corporation's stock recently reached a 52-week low of $148.09, reflecting a significant decline of nearly 50% over the past year and a 44% year-to-date drop. Despite strong Q1 financial results with sales of $762 million, surpassing estimates, analysts have adjusted price targets downward due to concerns about guidance and valuation. InvestingPro analysis suggests the stock may be undervalued and maintains a "GREAT" financial health score.
Why Insulet Is Dropping 6.7%: Barclays Maintains Underweight
Insulet Corporation's stock plunged 6.7% after nine analyst downgrades and price target cuts significantly lowered Wall Street's outlook for the company. Barclays downgraded the stock to Underweight, while other firms also reduced their price targets, indicating a fundamental reassessment of Insulet's near-term prospects. Investors should monitor for company disclosures regarding guidance revisions or competitive dynamics that may have prompted these analyst actions.
Why Insulet Is Dropping 6.7%: Barclays Maintains Underweight
Insulet Corporation (PODD) saw its stock plunge 6.7% after nine analyst firms downgraded their ratings and slashed price targets by an average of 27.8%. This coordinated action, including Barclays lowering its rating to Underweight, signals a significant reassessment of the company's near-term prospects. Investors are advised to monitor for company disclosure regarding potential guidance revisions or competitive dynamics that may have prompted these analyst resets.
Insulet Corp. stock underperforms Wednesday when compared to competitors
Shares of Insulet Corp. (PODD) fell by 6.01% on Wednesday, closing at $148.84. This underperformance occurred on a mixed trading day where the S&P 500 Index rose, but the Dow Jones Industrial Average declined. The stock's dip ended a two-day winning streak.
Insulet stock (US45784P1012): Benchmark initiates coverage as shares jump 3.4%
Shares of Insulet (PODD) climbed 3.4% after Benchmark initiated coverage, with Zacks Investment Research also highlighting the stock as a strong growth pick. Insulet, a leader in tubeless insulin delivery systems, traded at $158.82, despite being down significantly year-to-date and from its 52-week high. The company's core business model focuses on its Omnipod platform for diabetes management, targeting a growing market with its innovative, patient-centric technology.
Insulet stock (US45784P1012): Benchmark initiates coverage as shares jump 3.4%
Insulet Corporation (PODD) shares rose 3.4% after Benchmark initiated coverage, despite the stock being down 43.9% year-to-date. The company specializes in innovative tubeless insulin delivery systems, primarily the Omnipod, and holds a strong position in the US diabetes care market. This development highlights ongoing interest in Insulet's technology, which focuses on user-friendly solutions for diabetes management.
Some May Be Optimistic About Insulet's (NASDAQ:PODD) Earnings
Insulet Corporation's recent earnings report was disappointing due to soft headline numbers, but the article suggests that investors might be overlooking encouraging factors. A significant US$87m expense from unusual items negatively impacted profits, but these are often one-off and, if not repeated, could lead to higher profits next year. The company also demonstrates strong EPS growth, suggesting an understatement of its true earnings potential.
Why Insulet (PODD) Stock Is Trading Up Today
Insulet Corporation (PODD) stock rose 3.4% today after Benchmark initiated coverage with a "Buy" rating and a $250 price target. The company also announced the opening of its Middle East and North Africa regional headquarters, signaling strategic expansion. Despite today's gains, Insulet's stock is down 43.9% year-to-date and trading significantly below its 52-week high.
Why Insulet (PODD) Stock Is Trading Up Today
Insulet Corporation (PODD) stock rose 3.4% after Benchmark initiated coverage with a "Buy" rating and a $250 price target. The company also announced strategic expansion into the Middle East and North Africa with a new regional headquarters in Riyadh. Despite this positive news, Insulet shares are down 43.9% year-to-date and are trading significantly below their 52-week high.
Insulet Corp. stock outperforms competitors on strong trading day
Insulet Corp. (PODD) saw its stock rise by 2.71% to $158.35 on Tuesday, marking its second consecutive day of gains. This performance occurred on a mixed trading day where the Dow Jones Industrial Average increased slightly and the S&P 500 Index experienced a minor decline, indicating Insulet's outperformance relative to the broader market.
Benchmark Initiates Insulet at Buy With $250 Price Target
Benchmark has initiated coverage of Insulet Corporation (PODD) with a "Buy" rating and set a price target of $250. This news follows a series of recent price target adjustments from other financial institutions, reflecting varied outlooks on the medical device company specializing in insulin pump therapy systems. The article also provides a company profile, financial data points, and analyst consensus information for Insulet.
Benchmark reaffirms Insulet stock rating with $250 price target
Benchmark has reiterated its Buy rating on Insulet Corporation (NASDAQ:PODD) with a $250 price target, suggesting a significant upside from its current trading price near a 52-week low. Despite a 53% decline in the stock over the past six months, the company recently reported a strong 34% increase in sales, surpassing analyst estimates. This news comes amidst mixed sentiment from other analysts who have adjusted their price targets due to guidance and valuation concerns, although generally maintaining positive ratings.
Benchmark Reiterates Buy Rating on Insulet Corporation (PODD)
Benchmark analyst Bruce Jackson has reiterated a Buy rating on Insulet Corporation (PODD). The article is premium content, requiring a subscription or sign-in to view the full details of the analyst's report.
Insulet Corp Shs Unsponsored Brazilian Depositary Receipt Repr 0.03333333 Sh
This article focuses on the "Number of shareholders" data for Insulet Corp Shs Unsponsored Brazilian Depositary Receipt Repr 0.03333333 Sh (P2OD34) on the B3 exchange. It appears to be a page from a financial data platform, providing an overview of the stock's financial details, news, and community discussions. The main content indicates a placeholder for period-specific shareholder values and their changes.
Insulet Corporation (PODD) Stock Analysis: A 62% Potential Upside Beckons Investors
Insulet Corporation (PODD), a leader in diabetes care with its Omnipod insulin delivery systems, is attracting investor interest due to a potential 62.25% upside based on analyst target prices. Despite a recent stock decline, its strong financials, positive analyst sentiment, and focus on growth-oriented reinvestment signal promising long-term prospects. Investors should, however, evaluate market conditions and risks.
Wearable Skin Patch Market Size Propelled by 12.8% CAGR |
The Wearable Skin Patch Market is experiencing significant growth, projected to be propelled by a 12.8% CAGR from 2026-2033. This expansion is driven by the convergence of digital health, remote patient monitoring, and AI-driven clinical insights, with North America leading in adoption. Key opportunities exist in chronic disease management and platform-based companies combining hardware with SaaS analytics.
Insulet establishes Middle East regional headquarters in Riyadh, marking a strategic milestone in the Kingdom
Insulet Corporation, a global leader in tubeless insulin pump technology, has opened its Middle East and North Africa regional headquarters in Riyadh, Saudi Arabia. This strategic move deepens Insulet's commitment to the Kingdom's healthcare future, especially given Saudi Arabia's high rates of diabetes. The new headquarters will serve as a hub for clinical engagement, partner development, and talent investment, aiming to integrate advanced diabetes technology like the Omnipod 5 Automated Insulin Delivery System into the region's healthcare system.
